Clinical Trial Update: Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease [Phase 3]

View source ↗

Summary

This Phase 3 trial compared Symbicort pMDI with Formoterol Turbuhaler in COPD patients to determine exacerbation reduction. Results were posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Formoterol Turbuhaler (formoterol)
• Symbicort (budesonide/formoterol)

Snippet

Sponsor: AstraZeneca | Conditions: COPD Patients | Phase 3 | Status: COMPLETED | Results posted: 2017-06-12